Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
nutriflex lipid peri infusionsemulsion, 2500 ml
b. braun medical ag - glucosum, natrii dihydrogenophosphas, zinci acetas, isoleucinum, leucinum, lysinum anhydricum, methioninum, phenylalaninum, threoninum, tryptophanum, valinum, argininum, histidinum, alaninum, acidum asparticum, acidum glutamicum, glycinum, prolinum, serinum, natrii hydroxidum, natrii chloridum, natrii acetas, kalii acetas, magnesii acetas, calcii chloridum anhydricum, aminoacida, carbohydrata, materia crassa, natrium, kalium, calcium, magnesium, zincum, chloridum, phosphas, acetas, sojae oleum, triglycerida - infusionsemulsion, 2500 ml - i) glucoselösung: glucosum 176 g ut glucosum monohydricum 160 g, natrii dihydrogenophosphas 1.8 g ut natrii dihydrogenophosphas dihydricus 2.34 g, zinci acetas 11.14 mg ut zinci acetas dihydricus 13.25 mg, acidum citricum monohydricum, aqua ad iniectabile q.s. ad solutionem pro 1000 ml. ii) fettemulsion: sojae oleum 50 g, triglycerida media 50 g, lecithinum ex ovo, glycerolum, natrii oleas, aqua ad iniectabile q.s. ad emulsionem pro 500 ml. iii) aminosäurenlösung: isoleucinum 4.68 g, leucinum 6.26 g, lysinum anhydricum 4.52 g ut lysini hydrochloridum 5.68 g, methioninum 3.92 g, phenylalaninum 7.02 g, threoninum 3.64 g, tryptophanum 1.14 g, valinum 5.2 g, argininum 5.4 g, histidinum 2.5 g ut histidini hydrochloridum monohydricum 3.38 g, alaninum 9.7 g, acidum asparticum 3 g, acidum glutamicum 7 g, glycinum 3.3 g, prolinum 6.8 g, serinum 6 g, natrii hydroxidum 1.6 g, natrii chloridum 2.162 g, natrii acetas 0.656 g ut natrii acetas trihydricus 1.088 g, kalii acetas 5.886 g, magnesii acetas 0.856 g ut magnesii ac - nutrizione parenterale - synthetika
Unione Europea -
italiano -
EMA (European Medicines Agency)
pemetrexed baxter
baxter holding b.v. - pemetrexed disodium heptahydrate - carcinoma, non-small-cell lung; mesothelioma - agenti antineoplastici - malignant pleural mesotheliomapemetrexed baxter in combination with cisplatin is indicated for the treatment of chemotherapy naïve patients with unresectable malignant pleural mesothelioma. non-small cell lung cancerpemetrexed baxter in combination with cisplatin is indicated for the first line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5. pemetrexed baxter is indicated as monotherapy for the maintenance treatment of locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology in patients whose disease has not progressed immediately following platinum-based chemotherapy (see section 5. pemetrexed baxter is indicated as monotherapy for the second line treatment of patients with locally advanced or metastatic non-small cell lung cancer other than predominantly squamous cell histology (see section 5.
Svizzera -
italiano -
Swissmedic (Swiss Agency for Therapeutic Products)
ferro-gradumet compresse a rilascio prolungato
farmaceutica teofarma suisse sa - ferro(ii) - compresse a rilascio prolungato - ferrum(ii) 105 mg ut ferrosi sulfas desiccatus, methylis methacrylatis et methylis acrylatis polymerisatum, lactosum monohydricum 19.4 mg, povidonum k 30, magnesii stearas, e 171, e 127, hypromellosum, ethylcellulosum, saccharinum natricum, triethylis citras, sorbitani oleas, ricini oleum virginale, pro compresso obducto corresp., natrium 0.01 mg. - anemia da carenza di ferro con carenza di ferro accertata - synthetika
Italia -
italiano -
Ministero della Salute
elements diagnostic unit & apex locator
ormco corporation - localizzatori di forame apicale
Italia -
italiano -
Ministero della Salute
elements obturation unit
ormco corporation - compattatori per endodonzia
Italia -
italiano -
Ministero della Salute
materasso antidecubito modello elements bd. bf
b&t s.p.a. - materassi e traverse antidecubito
Italia -
italiano -
Ministero della Salute
materasso antidecubito modello elements pr. fp
b&t s.p.a. - materassi e traverse antidecubito